CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...
Hosted on MSN23h
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullishits gene-editing treatment for sickle cell disease and beta-thalassemia. Analysts responded positively to the results. According to The Fly, Barclays raised its price target on Vertex to $467 from ...
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
Fintel on MSN1h
Canaccord Genuity Upgrades Vertex Pharmaceuticals (VRTX)Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.
Investors were feeling zen on Wednesday, with no major news about Donald Trump's tariffs to worry about ahead of the monthly ...
(Reuters) - German software developer TeamViewer posted on Wednesday mid-term revenue growth targets after it closed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback